A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients
ENSAYO CLINICO COMERCIAL
Información del ensayo clínico
- Promotor: VIR BIOTECHNOLOGY INC
- Fase: III
- Comienzo de la ejecución: 30/10/2020
- Fin de la ejecución: 30/06/2021
- IP: JUAN PASQUAU LIAÑO